NIH R01 · 2024
Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer
PROJECT SUMMARY/ABSTRACT Current standard tri-modality therapy (chemotherapy, radiation, and surgery) for locally advanced rectal cancer is associated with high morbidity and only cures disease in about 75% of patients. We hypothesize that a biomarker-driven approach that gives matched targeted therapy to patients early in the treatment of locally advanced rectal cancers will lead to high anti-tumor activity and provide the chance to avoid radiation and/or surgery and its associated morbidities. We have already pioneered such an approach for mismatch repair deficient locally advanced rectal cancer, where clinical complete response was seen in all patients who completed 6 months of upfront…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.